Side-by-side · Research reference

GonadorelinvsHCG

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED7/61 cited

BFDA-ApprovedHUMAN-REVIEWED12/52 cited

Gonadorelin

GnRH Analogue · Diagnostic & Therapeutic

90 minPulsatile interval

73%Ovulation restorationTadesse 2026

2–4 minPlasma half-life

IV / SQ · Pulsatile Pump (Therapeutic) · Single Bolus (Diagnostic)

HCG

Glycoprotein Hormone · LH Mimetic

2,000 IUTypical dose (2×/wk)Konsam 2026 Zachariou 2026

70–90%Sperm induction rateHuijben 2026 Zachariou 2026

12–24 moTime to sperm appearanceHuijben 2026 Nariyoshi 2025

IM or SQ · 2–3×/week

01Mechanism of Action

Parameter

Gonadorelin

HCG

Primary target

GnRH receptors on anterior pituitary gonadotropes

LH receptors on testicular Leydig cellsSchröder-Lange 2025

Pathway

GnRH → Pituitary gonadotrope → LH/FSH secretion → Gonadal steroidogenesisSharma 2026

hCG → Leydig cell LH receptor → Intracellular cAMP → Steroidogenesis pathway activation → Testosterone synthesis

Downstream effect

Pulsatile LH/FSH release stimulates testicular testosterone or ovarian estradiol/progesterone synthesis; initiates folliculogenesis and spermatogenesisRobin 2026 Sharma 2026

Elevated intratesticular testosterone, restored spermatogenesis, virilization, secondary sex characteristic developmentKonsam 2026 Zachariou 2026

Feedback intact?

Yes — pulsatile delivery preserves negative feedback loops; continuous exposure desensitizes receptors

No — exogenous hCG bypasses hypothalamic-pituitary axis; endogenous LH remains suppressed

Origin

Synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) identical to native hypothalamic GnRH

Heterodimeric glycoprotein (alpha subunit shared with LH/FSH/TSH; beta subunit confers specificity). Available as urinary-derived or recombinant formulations.

Antibody development

—

Rare with recombinant; possible with urinary-derived formulations

02Dosage Protocols

Parameter

Gonadorelin

HCG

Diagnostic test (pituitary function)

100 mcg IV or SQ bolus

Measure baseline LH/FSH, then 30/60/90 min post-injection. Normal response: LH ≥2× baseline.

—

Therapeutic (hypothalamic hypogonadism)

5–20 mcg IV bolus every 90–120 minutes

Requires portable pulsatile pump. Dose individualized to achieve normal gonadotropin pulsatility.Robin 2026

—

Pulsatile interval

90 minutes (females) · 120 minutes (males)

Mimics physiological GnRH pulse frequency.

—

Route

IV preferred (therapeutic) · SQ acceptable (diagnostic)

Intramuscular or subcutaneousKonsam 2026

Duration

Continuous until pregnancy achieved or fertility goals met

3–6 month courses typical for ovulation induction.

—

Evidence basis

RCT / Expert consensus

RCT / Meta-analysis / FDA-approvedKonsam 2026 Huijben 2026

Half-life

2–4 minutes (plasma)

Necessitates frequent pulsatile administration.

—

Alternative protocols

Exogenous gonadotropins (hCG/hMG) often preferred due to convenience vs pump requirement

—

Hypogonadotropic hypogonadism (monotherapy)

—

2,000 IU IM/SQ 2–3×/weekKonsam 2026 Zachariou 2026

Titrate to normalize testosterone (300–1,000 ng/dL) or achieve target AMH ~7.4 ng/mL.

Combined therapy (hCG + FSH)

—

hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wkKonsam 2026 Nariyoshi 2025

Preferred for azoospermia; FSH added after initial hCG phase or from outset.

Triple therapy (experimental)

—

hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wk + testosterone 100 mg IM q2wkKonsam 2026

May accelerate virilization; reduces hCG requirements (~30% lower cumulative dose vs monotherapy).

Cryptorchidism (pediatric)

—

500–4,000 IU IM 2–3×/week for 3–6 weeks

Duration to sperm appearance

—

12–24 months (median ~18 mo)Huijben 2026 Zachariou 2026

Congenital HH may require longer treatment; acquired HH responds faster.

Monitoring

—

Serum testosterone, semen analysis q3–6mo, testicular ultrasound

Thickened seminiferous tubules (>300 μm) on ultrasound predict imminent sperm appearance.Nariyoshi 2025

03Metabolic / Fat Loss Evidence

Parameter

Gonadorelin

HCG

Fat loss mechanism

None — gonadorelin acts exclusively on reproductive axis

—

Indirect metabolic effects

Restoration of sex hormones may normalize body composition in hypogonadal states

Effect mediated by downstream testosterone/estradiol, not GnRH itself.

—

04Side Effects & Safety

Parameter

Gonadorelin

HCG

Injection site reaction

Erythema, irritation (pulsatile pump catheter site)

Pain, erythema (mild, transient)

Headache

Common with bolus administration

—

Nausea / abdominal discomfort

Transient, dose-related

—

Ovarian hyperstimulation syndrome (OHSS)

Risk with ovulation induction protocols; monitor follicular development via ultrasound

—

Multiple gestation

Increased risk with fertility protocols (twins ~10–15%)

—

Anaphylaxis

Rare hypersensitivity reaction

—

Pump malfunction / infection

Mechanical failure or catheter-site infection with long-term IV pump use

—

Receptor desensitization

Continuous (non-pulsatile) exposure paradoxically suppresses gonadotropinsRobin 2026

—

Gynecomastia

—

Aromatization of elevated testosterone to estradiol; dose-dependent

Testicular discomfort / Edema

—

Rapid testicular growth in hypogonadal males; usually self-limiting

Polycythemia

—

Elevated hematocrit from supraphysiological testosterone; monitor CBC

Mood / Libido changes

—

Variable; usually positive with normalization of testosterone

Acne / Oily skin

—

Androgen-mediated; dose-dependent

Prostate concerns

—

Monitor PSA in older males; hCG restores physiological testosterone (not supraphysiological)

Antibody formation

—

Rare with recombinant; possible with urinary-derived

Absolute Contraindications

Gonadorelin

·Pregnancy (except therapeutic infertility protocols)
·Hypersensitivity to gonadorelin or excipients
·Hormone-dependent tumors (prostate, breast) — risk of tumor stimulation via sex hormone elevation

HCG

·Androgen-dependent malignancy (prostate, breast cancer)
·Hypersensitivity to hCG or excipients
·Precocious puberty

Relative Contraindications

Gonadorelin

·Ovarian cysts or PCOS (monitor for OHSS)
·Pituitary adenoma or other sellar mass (may worsen with gonadotropin surge)

HCG

·Untreated obstructive sleep apnea
·Severe cardiovascular disease (polycythemia risk)
·History of thromboembolism

05Administration Protocol

Parameter

Gonadorelin

HCG

1. Diagnostic protocol

Administer 100 mcg IV or SQ bolus. Draw baseline LH/FSH, then at 30, 60, 90 minutes. Normal response: LH ≥2× baseline, FSH modest rise. Blunted response suggests pituitary pathology; exaggerated response may indicate primary hypogonadism.

Add sterile water or bacteriostatic water per manufacturer instructions. Typically 1–2 mL per 5,000–10,000 IU vial. Roll gently — do not shake. Solution should be clear.

2. Therapeutic pump setup (pulsatile)

Requires programmable infusion pump with IV catheter. Set pulse interval to 90 min (females) or 120 min (males). Bolus dose 5–20 mcg per pulse. Pump worn continuously; catheter site rotated every 48–72 hrs to prevent infection.

Intramuscular: ventrogluteal, vastus lateralis, or deltoid. Subcutaneous: abdomen, avoiding navel (2-inch radius). Rotate sites to prevent lipohypertrophy.

3. Reconstitution

Lyophilised gonadorelin reconstituted with sterile saline or provided diluent. Typically 0.8–3.2 mg dissolved in 8 mL for pump reservoir. Solution stable 7–14 days refrigerated.

Administer 2–3 times per week. Consistent weekly schedule recommended (e.g., Monday/Thursday or Monday/Wednesday/Friday).

4. Monitoring

For fertility protocols: ultrasound follicular tracking + serial estradiol/LH measurements. Adjust pulse dose to achieve mid-follicular LH 5–10 IU/L. Ovulation confirmed by progesterone rise or ultrasound.

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C. Bacteriostatic water extends shelf life to ~30 days; sterile water use within 72 hours.

5. Timing

Pulsatile therapy initiated at any point in cycle. Diagnostic test performed in morning (higher baseline LH). For ovulation induction, treatment begins early follicular phase.

IM: 21–23G, 1–1.5 inch. SQ: 25–27G, 5/8 inch. Inject slowly (30–60 seconds for IM).

06Stack Synergy

Gonadorelin

+ hCG (Human Chorionic Gonadotropin)

Multi-pathway

View hCG (Human Chorionic Gonadotropin) →

In hypogonadotropic hypogonadism protocols, gonadorelin restores pituitary LH/FSH pulsatility, while exogenous hCG directly stimulates Leydig cells (acting as LH mimetic) to maintain testosterone production. This dual approach ensures both central axis restoration and immediate gonadal steroidogenesis, preventing testicular atrophy during fertility treatment. hCG's longer half-life (24–36 hrs) complements gonadorelin's pulsatile short-acting profile.

Gonadorelin: 5–10 mcg IV every 120 min (pulsatile pump)
hCG: 1500–2000 IU SQ · 2–3× per week
Duration: 12–24 weeks for spermatogenesis induction
Primary benefit: Fertility restoration in hypothalamic hypogonadism with maintained testicular function

HCG

— no documented stacks